Business Description
ValiRx PLC
ISIN : GB00BLH13C52
Total Employee Number:
14Description
ValiRx PLC is a UK-based biopharmaceutical and life sciences company focused on advancing cutting-edge therapies in healthcare. The Company mainly engages in developing technologies and products in oncology therapeutics and diagnostics, with a focus on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It develops therapeutics across fields in oncology and has a portfolio of products in the pipeline, including GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in different stages of development.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 792 | |||||
Equity-to-Asset | 1.09 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -19.34 | |||||
Beneish M-Score | -4.14 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 45.6 | |||||
3-Year EPS without NRI Growth Rate | 45.6 | |||||
3-Year FCF Growth Rate | 43.3 | |||||
3-Year Book Growth Rate | -55.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 15.97 | |||||
9-Day RSI | 21.25 | |||||
14-Day RSI | 23.15 | |||||
3-1 Month Momentum % | -40.32 | |||||
6-1 Month Momentum % | -51.32 | |||||
12-1 Month Momentum % | -69.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.62 | |||||
Quick Ratio | 4.33 | |||||
Cash Ratio | 3.37 | |||||
Days Inventory | 680.68 | |||||
Days Sales Outstanding | 808.49 | |||||
Days Payable | 1177.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -102 | |||||
Shareholder Yield % | -47.6 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -19.36 | |||||
Operating Margin % | -5880.65 | |||||
Net Margin % | -7200 | |||||
EBITDA Margin % | -7022.58 | |||||
FCF Margin % | -4919.35 | |||||
OCF Margin % | -4874.19 | |||||
ROE % | -63.03 | |||||
ROA % | -67.01 | |||||
ROIC % | -78.41 | |||||
3-Year ROIIC % | -59.39 | |||||
ROC (Joel Greenblatt) % | -959.68 | |||||
ROCE % | -77.59 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.36 | |||||
EV-to-EBIT | -0.28 | |||||
EV-to-EBITDA | -0.31 | |||||
EV-to-Revenue | 21.45 | |||||
EV-to-FCF | -0.44 | |||||
Earnings Yield (Greenblatt) % | -357.14 | |||||
FCF Yield % | -79.68 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ValiRx PLC Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil £) | 0.031 | ||
| EPS (TTM) (£) | -0.005 | ||
| Beta | -2.3654 | ||
| 3-Year Sharpe Ratio | -0.92 | ||
| 3-Year Sortino Ratio | -1.29 | ||
| Volatility % | 78.71 | ||
| 14-Day RSI | 23.15 | ||
| 14-Day ATR (£) | 0.000149 | ||
| 20-Day SMA (£) | 0.001638 | ||
| 12-1 Month Momentum % | -69.17 | ||
| 52-Week Range (£) | 0.0013 - 0.00849 | ||
| Shares Outstanding (Mil) | 1,320.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ValiRx PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ValiRx PLC Stock Events
| Event | Date | Price (£) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-09-29 | In 76 days | ||
| General meeting for 2025 | 2026-07-17 10:00 | In 3 days | ||
| Annual report for 2025 | 2026-06-22 | 0.00 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-06-22 | 0.00 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-09-29 | 0.01 (+0.00%) | ||
| General meeting for 2024 | 2025-06-30 11:00 | 0.01 (-4.17%) | ||
| Annual report for 2024 | 2025-06-06 | 0.01 (+5.26%) | ||
| Fourth quarter earnings results for 2024 | 2025-06-06 | 0.01 (+5.26%) | ||
| Second quarter earnings results for 2024 | 2024-09-27 | 0.02 (-2.86%) | ||
| 0.008:1 Stock Split | 2020-04-06 | 0.05 (+0.00%) |
Show
Entries
ValiRx PLC Frequently Asked Questions
What is ValiRx PLC(LSE:VAL)'s stock price today?
The current price of LSE:VAL is £0.00. The 52 week high of LSE:VAL is £0.01 and 52 week low is £0.00.
When is next earnings date of ValiRx PLC(LSE:VAL)?
The next earnings date of ValiRx PLC(LSE:VAL) is 2026-09-29 Est..
Does ValiRx PLC(LSE:VAL) pay dividends? If so, how much?
ValiRx PLC(LSE:VAL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on ValiRx PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers